For the Inventor, By the Inventor

Enter assignee name

Abingdon, United Kingdom

Prolifix Limited

USPTO Granted Patents = 14

% Expired Patents = 7.1

Forward Citations = 43

Loading Chart...

Loading Chart...

16 inventors (with patents filed for the assignee):

Nicholas B La Thangue (5 out of 5 patents)

Rene Bernards (4 out of 6 patents)

Martin Eilers (2 out of 3 patents)

4. Lasantha R Bandara (2 out of 2 patents)

5. Karen Peukert (2 out of 2 patents)

6. Frank Haenel (2 out of 2 patents)

7. Susana De La Luna (2 out of 2 patents)

8. René Bernards (2 out of 2 patents)

9. Roderick L Beijersbergen (2 out of 2 patents)

10. Renate M Zwijsen (2 out of 3 patents)

11. Eleonore M Hijmans (1 out of 1 patent)

12. Réné Bernards (1 out of 1 patent)

13. Susane De La Luna (1 out of 1 patent)

14. Nicholas D La Thangue (1 out of 1 patent)

15. Rob J Michalides (1 out of 1 patent)

14 patents: Sort by Forward Citations

1. 7160981 - Peptide antagonists of DP transcription factors (2007-01-09),

2. 7022490 - Myc-binding zinc finger proteins, their preparation and their use (2006-04-04),

3. 6448376 - Transcription factor-E2F-5 (2002-09-10),

4. 6387649 - Assay for a regulator of cell cycle progression (2002-05-14),

5. 6368809 - E2F ubiquitination domain, and assays for inhibitors and enhancers of E2F ubiquitination (2002-04-09),

6. 6350572 - Interaction between cyclin D1 and steroid receptor coactivators and users thereof in assays (2002-02-26),

7. 6303335 - Transcription factor E2F-4 (2001-10-16),

8. 6268334 - Peptide antagonists of DP transcription factors (2001-07-31),

9. 6160091 - Myc-binding zinc finger proteins, their preparation and their use (2000-12-12),

10. 6159691 - Assay for a putative regulator of cell cycle progression (2000-12-12),

11. 6045999 - Transcription factor E2F-4 (2000-04-04),

12. 6033843 - Interaction of cyclin D1 and estrogen receptor and its use in assays (2000-03-07),

13. 5985283 - Adenovirus E1A-Associated protein BS69, inhibitor of E1A-transactivation (1999-11-16),

14. 5859199 - Transcription factor DP-3 and isoforms thereof (1999-01-12),

Company Overview

Prolifix Limited, based in Abingdon, GB, specializes in the development of innovative solutions in the field of medical technology. The company focuses on enhancing patient care through advanced medical devices and systems that improve diagnostic and therapeutic outcomes. With a commitment to research and development, Prolifix aims to address critical healthcare challenges by leveraging cutting-edge technology and expertise in biomedical engineering, contributing to the evolution of healthcare practices.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

14 Patents

#15 in Abingdon

#1,268 in United Kingdom

#42,249 in the World

Abingdon, United Kingdom

Prolifix Limited

Forward Citations = 43

16 inventors:

Nicholas B La Thangue (5 out of 5 patents)

Rene Bernards (4 out of 6 patents)

Martin Eilers (2 out of 3 patents)

4. Lasantha R Bandara (2 out of 2 patents)

5. Karen Peukert (2 out of 2 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Prolifix Limited. Retrieved from https://idiyas.com/company/prolifix

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…